(lp0
S'Why XenoPort, Inc. Is Skyrocketing 56.6% Today Motley Fool - May 23, 2016 What: After XenoPort, Inc.  announced that it has agreed to be acquired for $7.03 per share in cash, its shares are soaring 56.6% today.XenoPort, Inc.  Stock Roars 56% on Generous Buyout - Investorplace.com'
p1
aS'Why Xenoport, Inc. Stock Jumped 61.1% in May Motley Fool - Jun 4, 2016 What: Shares of Xenoport, Inc. , a commercial-stage biotech struggling to expand its pipeline, jumped a whopping 61.1% last month, according to data from S&amp;P Global Market Intelligence.'
p2
aS'XenoPort: Buyout Appears Imminent Seeking Alpha - Feb 18, 2016 XenoPort, Inc.  is a biopharmaceutical company focused on commercializing HORIZANT for the treatment of moderate-to-severe primary restless legs syndrome  and postherpetic neuralgia  in adults in the United States.'
p3
aS'Why XenoPort, Inc. Shares Tanked Today Motley Fool - Feb 3, 2015 What: Shares of XenoPort , a biopharmaceutical company focused on developing therapies to treat neurological disorders, tanked as much as 13% during the trading day after disclosing that it had completed a convertible senior note offering.'
p4
aS"BioSurplus To Auction Research Equipment from the Laboratories of XenoPort, Inc. PR Newswire  - May 24, 2016 SAN DIEGO, May 24, 2016 /PRNewswire/ -- BioSurplus, America's leader in used lab equipment, announced today that it will be holding a timed online auction of lab equipment from XenoPort, Inc.'s discontinued research facility in Northern California."
p5
aS"Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort Business Wire  - Jul 5, 2016 ATLANTA &amp; SANTA CLARA, Calif.----Arbor Pharmaceuticals, LLC  and XenoPort, Inc.   today announced the successful completion of Arbor's tender offer to purchase all issued and outstanding shares&nbsp;..."
p6
aS'XenoPort Investor Clinton Group Urges Changing Focus, CEO Bloomberg - Oct 15, 2013 XenoPort Inc., the maker of the drug Horizant to treat restless-legs syndrome, should shift spending to an experimental multiple sclerosis treatment and replace its chief executive officer, shareholder Clinton Group Inc. said in a letter to management.Clinton Group Calls on Xenoport to Hire a New CEO and Focus on Promising Drug ... - PR Newswire '
p7
aS'XENOPORT SHAREHOLDER NOTICE: Faruqi &amp; Faruqi, LLP Announces the Investigation ... Business Wire  - May 26, 2016 NEW YORK----Juan E. Monteverde, a partner at Faruqi &amp; Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Xenoport, Inc. &nbsp;...'
p8
aS'Biopharmaceutical company Xenoport explores sale: sources Reuters - Jan 21, 2016 Xenoport Inc XNPT.O, a U.S. biopharmaceutical company focused primarily on treatments for restless leg syndrome, is in the early stages of exploring a potential sale, according to people familiar with the matter.'
p9
aS"XenoPort: Biogen's Little Brother And More Seeking Alpha - Jan 18, 2013 XenoPort  will deliver Phase III trial results for its lead pipeline candidate, Arbaclofen Placarbil, in early 2Q, and the company is moving forward on re-launching its approved restless leg treatment Horizant in the U.S."
p10
a.